title: Inflammatory cytokine release in patients with unstable angina after coronary angioplasty.
abstract: The aim of the present study was to investigate inflammatory cytokine release and the interaction with platelets in patients with unstable angina (UA) after coronary angioplasty. In 50 patients with stable angina (SA) and 58 patients with UA, serial venous blood samples were obtained immediately before, and 30 minutes, 4, 12, 24, 48 and 72 hours, and 7 days after coronary angioplasty. Plasma concentrations of IL-8 and vWF were determined by immunoassay, while the expression of CD11 b/CD18 on monocytes and the expression of CD41 on platelets were assessed by flow cytometry. Differences in the baseline plasma concentrations of IL-8, vWF and CD11b/CD18, CD41 were found in the UA and SA groups before angioplasty (101.1 +/- 31.28 pg/mL to 55.8 +/- 17.24 pg/mL, 137.67 +/- 38.14% to 107.40 +/- 28.67% and 318.67 +/- 36.85 MFI to 240.72 +/- 28.43 MFI, 147.5 +/- 23.18 MFI to 104.43 +/- 26.68 MFI all p < 0.05). The peak plasma levels of IL-8 (172.24 +/- 37.82 pg/mL at 12 hours) and vWF (256 +/- 42.32% at 4 hours) significantly increased after coronary angioplasty (both p < 0.01), and were associated with significant time course increases in surface expression of CD11b/CD18 (p < 0.01) and CD41 (p < 0.01). The levels of plasma IL-8 and vWF were significantly higher pre- and post-procedure in UA patients with lesion type C compared to types A or B (p < 0.05), but there were no differences for pre-procedure in the SA group patients with different lesion types (p > 0.05). There were significant correlations between plasma IL-8 and monocyte CD11b/CD18, vWF and CD41 in the UA group (r = 0.5248, r = 0.6240 both p < 0.01, respectively). The findings demonstrate increases in plasma IL-8 and CD11b/CD18 as inflammatory mediators, vWF and CD41 as the abnormal coagulation activity may therefore yield a rationale for pharmacological anticytokines in patients with UA after coronary angioplasty.
authors.affiliation: Cardiac Center, Hebei Provincial People's Hospital of Hebei Medical University, Shijiazhuang, China.
authors.forename: Xiaoyong
authors.initials: X
authors.lastname: Qi
authors.forename: Yingxin
authors.initials: Y
authors.lastname: Peng
authors.forename: Jian
authors.initials: J
authors.lastname: Gu
authors.forename: Shuren
authors.initials: S
authors.lastname: Li
authors.forename: Shiling
authors.initials: S
authors.lastname: Zheng
authors.forename: Jianqing
authors.initials: J
authors.lastname: Zhang
authors.forename: Tianhong
authors.initials: T
authors.lastname: Wang
mesh_terms: D000368:Aged; D000789:Angina, Unstable / Q000097:blood* / Q000628:therapy*; D015906:Angioplasty, Balloon, Coronary; D018821:CD18 Antigens / Q000097:blood; D016207:Cytokines / Q000097:blood*; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D016209:Interleukin-8 / Q000097:blood; D016177:Macrophage-1 Antigen / Q000097:blood; D008297:Male; D008875:Middle Aged; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000032:analysis; D014841:von Willebrand Factor / Q000032:analysis
chemical_list: D018821:CD18 Antigens; D016207:Cytokines; D016209:Interleukin-8; D016177:Macrophage-1 Antigen; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D014841:von Willebrand Factor